Cardiovascular safety of MnDPDP and MnCl2

Acta Radiologica

Volumn 38, Issue 4 PART 2, 1997, Pages 740-749

  Jynge, Per ^a,e   Brurok, H ^a   Asplund, A ^b   Towart, R ^c   Refsum, H ^d   Karlsson, J O G ^a,d  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b LINKÖPING UNIVERSITY   (Sweden)

^c Nycomed Holdings AS   (Austria)

^d NYCOMED IMAGING AS   (Norway)

^e NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Cardiovascular effects; Cardiovascular effects, mangafodipir trisodium; MR imaging, contrast media

Indexed keywords

CHLORIDE; CONTRAST MEDIUM; DRUG DERIVATIVE; EDETIC ACID; MANGANESE; MANGANESE CHLORIDE; MANGANESE DERIVATIVE; N,N' BIS(PYRIDOXAL 5 PHOSPHATE)ETHYLENEDIAMINE N,N' DIACETIC ACID; N,N'-BIS(PYRIDOXAL-5-PHOSPHATE)ETHYLENEDIAMINE-N,N'-DIACETIC ACID; PYRIDOXAL 5 PHOSPHATE;

ANIMAL; CARDIOVASCULAR SYSTEM; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; HUMAN; IN VITRO STUDY; INTOXICATION; REVIEW; SAFETY;

ANIMALS; CARDIOVASCULAR SYSTEM; CHLORIDES; CONTRAST MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; EDETIC ACID; HUMANS; MANGANESE; MANGANESE COMPOUNDS; MANGANESE POISONING; PYRIDOXAL PHOSPHATE; SAFETY;

EID: 0031179953     PISSN: 02841851     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841859709172407     Document Type: Article

References (49)

1. 2+ on neonatal and adult rat heart. Initial depression and late augmentation of contractile force. Eur. J. Pharmacol. 222 (1992), 223.
2. ARCHIBALD F. S. & FRIDOWICH I.: The scavenging of superoxide radical by manganous complexes. In vitro. Arch. Biochem. Biophys. 214 (1982), 452.
3. 2,-induced endothelium-dependent relaxation in bovine mesenteric arteries. J. Pharmacol. Exp. Ther. 271 (1994), 609.
4. BERNARDINO M. E., YOUNG S. W., LEE J. K. T. et al.: Hepatic MR imaging with MnDPDP. Safety, image quality and sensitivity. Radiology 183 (1992), 53.
5. BOLTON T. B.: Mechanisms of action of neurotransmitters and other substances on smooth muscle. Physiol. Rev. 59 (1979), 606.
6. 2 upon cardiac function. An experimental study in the Langendorff perfused rat heart. Invest. Radiol. 30 (1995), 159.
7. 2 on cardiac energy metabolism and Mn-accumulation. An experimental study in the isolated perfused rat heart. Accepted for publication in Invest. Radiol. (1997).
8. BRUTSAERT D. L.: Endocardial and coronary endothelial control of cardiac performance. NIPS 8 (1993), 82.
9. CHAPMAN R. A. & ELLIS D.: Uptake and loss of manganese from perfused frog ventricles. J. Physiol. (London) 272 (1977), 355.
10. CONRAD L. L., TRENDLEY R. L. & BAXTER D. J.: Positive inotropic effect of manganese in dog myocardium. Am. J. Physiol. 210 (1966), 357.
11. CORABOEUF E. & VASSORT G.: Effects of some inhibitors of ionic permeabilities on ventricular action potential and contraction of rat and guinea pig hearts. J. Electrocardiol. 1 (1968), 19.
12. DAVIDSSON L., LONNERDAL B., SANDSTRÖM B., KUNZ C. & KEEN C. L.: Identification of transferrin as the major plasma carrier protein for manganese introduced orally or intravenously or after in vitro addition in the rat. J. Nutr. 119 (1989), 1461.
13. 2+ across the cell membrane in the guinea pig myocardium. Its effect on the mechanical response. Circ. Res. 36 (1975), 713.
14. ELIZONDO G., FRETZ, C. J., STARK D. D. et al.: Preclinical evaluation of MnDPDP. New paramagnetic hepatobiliary contrast agent for MR imaging. Radiology 178 (1991), 73.
15. FAWWAS R., BOHDIEWICZ P., LAVALLEE D. et al.: Use of metalloporphyrins in diagnostic imaging. Nucl. Med. Biol. 17 (1990), 65.
16. FURCHGOTT R. F., JOTHIANANDAN D. & GIDARI A. S.: The mechanism of action of LY 83583, a selective inhibitor of endothelium-dependent relaxation, p. 119. In: Proc. 31st Congr. Physiol. Sci., Helsinki 1981.
17. 14C labelled MnDPDP in rats and dogs. Abstract p. 251. ESMRMB 10th Ann. Congr., Rome 1993.
18. HUNTER D. R., HAWORTH R. A. & BERKOFF H. A.: Cellular manganese uptake by the isolated perfused rat heart. A probe for the sarcolemmal calcium channel. J. Mol. Cell. Cardiol. 13 (1981), 823.
19. HUSTVEDT S. O., GRANT D., SOUTHON T. E. & ZECH K.: Plasma pharmacokinetics, tissue distribution and excretion of MnDPDP in the rat and dog after intravenous administration. Acta Radiol. 38 (1997), 690.
20. JYNGE P., BRUROK H., ASPLUND A. et al.: Cardiovascular safety of MnDPDP. Experience from ex vivo and in vivo animal experiments, p. 83. In: New developments in contrast agent research. Edited by P. A. Rinck & R. N. Muller. 4th Special Topic Semin. Eur. Magn. Reson. Forum, Mons 1995.
21. 2 in dogs with acute ischaemic heart failure. Acta Radiol. 38 (1997), 750.
22. KASTEN T. P., SETTLE S. L., MISKO T. P., CURRIE M. G. & NICKOLS G. A.: Manganese potentiation of nitric oxide mediated vascular relaxation. Eur. J. Pharmacol. 253 (1994), 35.
23. KEEN C. L., BALY D. L. & LONNERDAL B.: Metabolic effects of high doses of manganese in rats. Biol. Trace Elem. Res. 6 (1984), 309.
24. KLIEGFIELD P., CHARASH B., PLACEK E. & Sos T. A.: Antiarrhythmic effects of manganese chloride in infarcted dogs with observations of the dose-related response of heart rate and ventricular pressure. J. Pharmacol. Ther. 218 (1981), 289.
25. KORC M.: Manganese homeostasis in humans and its role in disease states. In: Essential and toxic trace elements in human health and disease, p. 253. Edited by A. S. Prasad. John Wiley & Sons, Chichester 1988..
26. LANGER G. A., SERENA S. D. & NUDD L. M.: Localization of contractile-dependent Ca. Comparison of Mn and verapamil in cardiac and skeletal muscle. Am. J. Physiol. 229 (1975), 1003.
27. LAUTERBUR P. C., MENDONCA D. M. H. & RUDIN A. M.: Argumentation of water proton spin-lattice relaxation rates by the in vivo addition of paramagnetic ions. In: Frontiers of biological energetics, p. 752. Edited by P. C. Duton. Academic Press, New York 1978.
28. LIM K. O., STARK D. D., LEESE P. T., PFEFFERBAUM A., ROCKLAGE S. M. & QUAY S. C.: Hepatobiliary MR imaging. First human experience with MnDPDP. Radiology 178 (1991), 79.
29. MATSANUGA K. & FURCHGOTT R. F.: Responses of rabbit aorta to nitric oxide and superoxide generated by ultraviolet irradiation of solutions containing inorganic nitrite. J. Pharmacol. Exp. Ther. 259 (1991), 1140.
30. MONCADA S., PALMER R. M. & HIGGS E. A.: Nitric oxide. Physiology, pathophysiology and pharmacology. Pharmacol. Rev. 43 (1991), 109.
31. MUHLER A.: Assessment of myocardial perfusion using contrast-enhanced MR imaging. Current status and future developments. MAGMA 3 (1995), 21.
32. MURAD F.: Drugs used for the treatment of angina. In: Goodman and Gilman's The pharmacological basis of therapeutics, p. 764. Edited by A. G. Gilman et al. Pergamon Press, New York 1990.
33. ++ binding by plasma proteins. Int. J. Peptide Protein Res. 5 (1973), 279.
34. NELSON R. C., CHEZMAR J. L., NEWBERRY L. B., MALKO J. A., GEDGAUDAS-MCCLEES R. K. & BERNARDINO M. E.: Manganese dipyridoxyl diphosphate. Effect of dose, time and pulse sequence on hepatic enhancement in rats. Invest. Radiol. 26 (1991), 569.
35. ØKSENDAL A. N. & JYNGE P.: Myocardial protection by micromolar manganese in the calcium paradox and additive effects of verapamil. Basic Res. Cardiol. 81 (1986), 581.
36. PAYET M. D., SCHAMME O. F., RUIZ-CERETTE E. & DENIERS J. M.: Inhibitory action of blockers of the slow inward current in the rat myocardium, a study in the steady state and of rate of action. J. Mol. Cell. Cardiol. 12 (1980), 187.
37. POMEROY O. H., WENDLAND M. F., WAGNER S. et al.: Magnetic resonance imaging of acute myocardial ischemia using a manganese chelate, MnDPDP. Invest. Radiol. 24 (1989), 531.
38. ROCKLAGE S. M. & VANWAGONER M.: Hepatobiliary contrast agents. An overview of the development of manganese dipyridoxyl diphosphate (MnDPDP). In: Liver imaging, current trends, and new techniques, p. 374. Edited by J. T. Ferrucci & D. D. Stark. Andover Medical Publishers Inc., Boston 1990.
39. SAEED M., WENDLAND M. F, TAKEHARA Y. & HIGGINS C. B.: Reversible and irreversible injury in the reperfused myocardium. Differentiation with contrast material-enhanced MR imaging. Radiology 175 (1990), 633.
40. SCHAEFER S., LANGE R. A., GUTEKUNST D. P., PARKEY R. W., WILLERSON J. T. & PESHOCK R. M.: Contrast-enhanced magnetic resonance imaging of hypoperfused myocardium. Invest. Radiol. 26 (1991), 551.
41. SELLEVOLD O. F. M., JYNGE P. & AARSTAD K.: High performance liquid chromatography. A rapid isocratic method for the determination of creatine compounds and adenine nucleotides in myocardial tissue. J. Mol. Cell. Cardiol. 18 (1986), 517.
42. SHAW D. D.: Summary of the clinical experience with S095 injection (manganese dipyridoxyl diphosphate, MnDPDP). In: New developments in contrast agent research, p. 15. Edited by P. A. Rinck & R. N. Muller. Proc. 3rd Special Topic Semin. Eur. Magn. Reson. Forum, EMRF, Mons 1992.
43. SPERELAKIS N.: Physiological principles of cardiac toxicology. In: Principles of cardiac toxicology, p. 71. Edited by S. I. Baskin. CRC Press, Boca Raton 1991.
44. TAKEYA K. & REITER M.: Effect of divalent manganese ions on action potential and contractility of cardiac muscle. Naunyn Schmiedebergs Arch. Pharmacol. 275 (1972), 213.
45. TOFT K. G., HUSTVEDT S. O., GRANT D. et al.: Metabolism and pharmacokinetics of MnDPDP in man. Acta Radiol. 38 (1997), 677.
46. TORRES C. G., LUNDBY B., TUFTE STERUD A., MCGiLL S., GORDON P. B. & STRAND BJERKNES H.: MnDPDP for MR imaging of the liver. Results from the European phase III studies. Acta Radiol. 38 (1997), 631.
47. 2 in the conscious beagle dog. Can. J. Physiol. Pharmacol. 72 Suppl. 1 (1994), 186.
48. WANG C., GORDON P. B., HUSTVEDT S. O. et al.: MR imaging properties and pharmacokinetics of MnDPDP in healthy volunteers. Acta Radiol. 38 (1997), 665.
49. WOLF G. L. & BAUM L.: Cardiovascular toxicity and tissue proton T1 response to manganese injection in the dog and rabbit. AJR 141 (1983), 193.